What do systematic reviews say?

Intervention not reported

• Selective serotonin reuptake inhibitors for premenstrual syndrome 2013 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 657 participants
  Moderate

Intervention not reported

The intervention probably leads to higher low dose SSRI versus placebo Luteal or continuous administration (moderate certainty).

• Selective serotonin reuptake inhibitors for premenstrual syndrome 2013 · Cochrane Headline outcomes only
  OR 1.76 [1.13, 2.75]
  7 studies · 1301 participants
  Moderate

Intervention not reported

The intervention probably leads to higher mod dose SSRI versus placebo Luteal or continuous administration (moderate certainty).

• Selective serotonin reuptake inhibitors for premenstrual syndrome 2013 · Cochrane Headline outcomes only
  OR 2.55 [1.84, 3.53]
  15 studies · 2447 participants
  Moderate

Intervention not reported

The intervention probably leads to higher high dose SSRIs versus placebo Continuous administration (moderate certainty).

• Selective serotonin reuptake inhibitors for premenstrual syndrome 2013 · Cochrane Headline outcomes only
  RR 6.35 [2.88, 14]
  1 study · 231 participants
  Moderate

Intervention not reported

• Triptans for acute cluster headache 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

• Triptans for acute cluster headache 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

• Triptans for acute cluster headache 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Triptans for acute cluster headache 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

It is very uncertain whether the intervention changes pain‐free at 15 mins (very low certainty).

• Triptans for acute cluster headache 2013 · Cochrane Headline outcomes only
  RR 2.6 [0.8, 8.5]
  Studies not reported
  Very low

Intervention not reported

• Triptans for acute cluster headache 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

It is very uncertain whether the intervention changes headache relief at 15 mins (very low certainty).

• Triptans for acute cluster headache 2013 · Cochrane Headline outcomes only
  RR 2.2 [0.99, 4.67]
  Studies not reported
  Very low

Intervention not reported

It is very uncertain whether the intervention changes at least one AE (very low certainty).

• Triptans for acute cluster headache 2013 · Cochrane Headline outcomes only
  RR 1.8 [1.2, 2.8]
  Studies not reported
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Triptans for acute cluster headache 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Triptans for acute cluster headache 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Triptans for acute cluster headache 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Intervention not reported

The review found no eligible studies for this question.

• Triptans for acute cluster headache 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

TDF vs AZT

TDF showed no clear difference in serious adverse events compared with AZT (high certainty).

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 0.92 [0.6, 1.43]
  2 studies · 586 participants
  High

TDF vs AZT

TDF showed no clear difference in virologic response compared with AZT (high certainty).

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 2.04 [0.17, 24.84]
  2 studies · 586 participants
  High

TDF vs AZT

TDF probably leads to higher adherence/tolerability/retention compared with AZT (moderate certainty).

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 1.17 [1.06, 1.29]
  2 studies · 586 participants
  Moderate

TDF vs AZT

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 515 participants
  Moderate